Taiwan Liposome’s Liver Cancer Drug Put on Fast Track in China
Lipotecan®, an innovative liver cancer drug developed by Taiwan Liposome Company, was accepted into the SFDA’s Green Path program, a fast-track approval process. TLC said Lipotecan is a new chemical entity with multiple mechanisms of action against tumors that has shown positive results in ex-China Phase II trials. TLC expects to start a China Phase II trial later this year. More details.... Stock Symbol: (TW: 4152) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here